Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.68 |
| ▸ | CES1 | P23141 | 5/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772247 | 1.00 | CES2 (0.68) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL1975197 | 0.98 | CES2 (0.65) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL3440833 | 0.81 | CES2 (0.74) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL3184940 | 0.81 | CES2 (1.00) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL29593208 | 0.81 | CES2 (0.65) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL13461 | 0.81 | CES2 (0.65) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL16953030 | 0.81 | CES2 (0.60) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL1067211 | 0.80 | THRB (0.52) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL1642296 | 0.80 | KAT6A (0.47) | CES2CES1BCHEHPGDKMT2A | |
| SCHEMBL2642229 | 0.80 | KMT2A (0.50) | CES2CES1BCHEHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114950159-B | Preparation method of aromatic polymer separation membrane based on super acid catalysis | 南京工业大学 | 2023-06-06 | — | — | CN | claimed |
| CN-114950159-A | Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation | 南京工业大学 | 2022-08-30 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| CN-111148731-B | Fluorophenyl beta-hydroxyethylamine and its use in the treatment of hyperglycaemia | 阿托基公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | US | disclosed |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER (US) | 2024-06-06 | — | — | US | disclosed |
| EP-1606289-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272699-A1 | Acrylonitrile derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2005-12-08 | — | — | US | disclosed |
| WO-2005091752-A2 | ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004072069-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
| EP-1322616-A2 | QUINOLINE-(C=O)-(DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002018341-A2 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-4997840-A | Quinolone sulphonates having antihypertensive activity | THE BOOTS COMPANY, PLC (GB) | 1991-03-05 | — | — | US | disclosed |
| EP-0330340-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PRKAG1, PRKAG2, PRKAB1 | CES2 3030/4885CES1 2091/4885BCHE 4605/4885 |
| US-20240199558-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-20050272699-A1 | Acrylonitrile derivatives for inflammation and immune-related uses | IL1B, IL6, TLR4 | CES2 431/4885CES1 751/4885BCHE 3823/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | CES2 3829/4885CES1 4432/4885BCHE 4871/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | CES2 1535/4885CES1 545/4885BCHE 4062/4885 |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885BCHE 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.